Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 59
Filter
Add more filters










Publication year range
1.
Neuroimage ; 297: 120709, 2024 Jun 25.
Article in English | MEDLINE | ID: mdl-38936650

ABSTRACT

INTRODUCTION: The extended practice of meditation may reduce the influence of state fatigue by changing neurocognitive processing. However, little is known about the preventive effects of one-session brief focused attention meditation (FAM) on state fatigue in healthy participants or its potential neural mechanisms. This study examined the preventive effects of one-session brief FAM on state fatigue and its neural correlates using resting-state functional MRI (rsfMRI) measurements. METHODS: We randomly divided 56 meditation-naïve participants into FAM and control groups. After the first rsfMRI scan, each group performed a 10-minute each condition while wearing a functional near-infrared spectroscopy (fNIRS) device for assessing brain activity. Subsequently, following a second rsfMRI scan, the participants completed a fatigue-inducing task (a Go/NoGo task) for 60 min. We evaluated the temporal changes in the Go/NoGo task performance of participants as an indicator of state fatigue. We then calculated changes in the resting-state functional connectivity (rsFC) of the rsfMRI from before to after each condition and compared them between groups. We also evaluated neural correlates between the changes in rsFC and state fatigue. RESULTS AND DISCUSSION: The fNIRS measurements indicated differences in brain activity during each condition between the FAM and control groups, showing decreased medial prefrontal cortex activity and decreased functional connectivity between the medial prefrontal cortex and middle frontal gyrus. The control group exhibited a decrement in Go/NoGo task performance over time, whereas the FAM group did not. These results, thus, suggested that FAM could prevent state fatigue. Compared with the control group, the rsFC analysis revealed a significant increase in the connectivity between the left dorsomedial prefrontal cortex and right superior parietal lobule in the FAM group, suggesting a modification of attention regulation by cognitive effort. In the control group, increased connectivity was observed between the bilateral posterior cingulate cortex and left inferior occipital gyrus, which might be associated with poor attention regulation and reduced higher-order cognitive function. Additionally, the change in the rsFC of the control group was related to state fatigue. CONCLUSION: Our findings suggested that one session of 10-minute FAM could prevent behavioral state fatigue by employing cognitive effort to modify attention regulation as well as suppressing poor attention regulation and reduced higher-order cognitive function.

2.
Biol Pharm Bull ; 46(7): 964-968, 2023.
Article in English | MEDLINE | ID: mdl-37394646

ABSTRACT

Trastuzumab is a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) that is indicated for the treatment of HER2-positive breast cancer. The administration of biologics, such as trastuzumab, frequently causes infusion reactions (IRs) with fever and chills. This study aimed to clarify the risk factors for IRs in trastuzumab therapy. Between March 2013 and July 2022, 227 patients with breast cancer who started trastuzumab therapy were included in this study. The severity of IRs was graded according to the Common Terminology Criteria for Adverse Events, Version 5.0. The incidence of IRs in trastuzumab therapy was 27.3% (62/227). Dexamethasone administration was significantly different between the IR and non-IR groups in patients receiving trastuzumab therapy (univariate analysis, p < 0.001; multivariate analysis, p = 0.0002). Without dexamethasone, the severity of IRs in the pertuzumab combination group (Grade 1, 8/65; Grade 2, 23/65) was significantly higher than that in the non-pertuzumab group (Grade 1, 9/37; Grade 2, 3/37; p < 0.05). Our findings suggest that the risk of IRs is significantly higher in patients not premedicated with dexamethasone in trastuzumab therapy and that the concomitant use of pertuzumab without dexamethasone increases the severity of IRs caused by trastuzumab.


Subject(s)
Breast Neoplasms , Humans , Female , Trastuzumab/adverse effects , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Receptor, ErbB-2/metabolism , Risk Factors , Dexamethasone/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use
3.
eNeuro ; 10(6)2023 06.
Article in English | MEDLINE | ID: mdl-37221088

ABSTRACT

Despite the significant health consequences of anxiety, the neural basis of regulation for personal anxious events is not well understood. We examined brain activity and functional connectivity during cognitive emotion regulation strategies (reappraisal and acceptance) for personal anxious events. Functional MRI (fMRI) data were obtained while 35 college students were thinking about (the control condition), reappraising, or accepting their own anxiety-provoking situations. Although reappraisal and acceptance decreased anxiety, no statistically significant differences were observed in the brain activation levels between cognitive emotion regulation strategies and the control condition. However, acceptance decreased activation in the posterior cingulate cortex and precuneus more than reappraisal. Moreover, functional connectivity with the amygdala and ventral anterior insula distinguished the emotion regulation strategies for anxiety. Reappraisal showed stronger negative functional connectivity with the amygdala and cognitive control regions than other strategies. In addition, reappraisal had negative functional coupling between the ventral anterior insula and temporal pole compared with acceptance. In contrast, acceptance showed stronger positive functional coupling between the ventral anterior insula and precentral and postcentral gyrus compared with the control condition. Our findings contribute to the understanding of emotion regulation processes by revealing the brain activity and functional connectivity patterns in reappraisal and acceptance for personal anxious events.


Subject(s)
Anxiety , Brain , Humans , Brain/diagnostic imaging , Anxiety/diagnostic imaging , Amygdala/physiology , Gyrus Cinguli/diagnostic imaging , Anxiety Disorders , Brain Mapping , Magnetic Resonance Imaging , Emotions/physiology
4.
Cancer Chemother Pharmacol ; 91(1): 25-31, 2023 01.
Article in English | MEDLINE | ID: mdl-36401659

ABSTRACT

PURPOSE: Pertuzumab (Per) is a humanized monoclonal antibody used in combination with trastuzumab (Tra) in the treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer. The administration of biologics, such as Tra and Per, frequently causes infusion reactions (IRs) with fever and chills. This study aimed to clarify the characteristics of and risk factors for IRs in Tra + Per combination therapy. METHODS: Between March 2013 and December 2019, 64 patients with breast cancer who started Tra + Per combination therapy were included in the study. The severity of IRs was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. RESULTS: The incidence of IRs in the Tra + Per combination therapy was 48.4% (31/64). The severity of IRs in the Tra + Per combination therapy was Grade 1 (9 patients) and Grade 2 (22 patients). Lymphocyte counts were significantly different between the IR and non-IR groups in patients receiving Tra + Per combination therapy (univariate analysis, p = 0.006; multivariate analysis, p = 0.050). ROC curve analysis found the cutoff value of lymphocyte counts were 1.60 (× 103/µL). The incidence of IRs in the lymphocyte counts ≥ 1.60 group was significantly higher than that in the lymphocyte counts < 1.60 group (p < 0.001). CONCLUSION: Our study indicates that the severity of IRs in most patients is moderate or less and the risk of IRs is higher in patients with higher lymphocyte counts (≥ 1.60 × 103/µL).


Subject(s)
Breast Neoplasms , Humans , Female , Trastuzumab , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Incidence , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Receptor, ErbB-2/metabolism , Risk Factors
5.
Neuroimage ; 257: 119334, 2022 08 15.
Article in English | MEDLINE | ID: mdl-35643265

ABSTRACT

Appropriate emotion regulation is crucially involved in mental and physical health. The neural basis of negative but not positive emotion regulation has been well investigated. Several strategies should be compared to elucidate the neural correlates of positive emotion regulation. However, there are no studies on multiple positive emotion regulation strategies. We aimed to investigate the neural correlates of positive emotion regulation with multiple emotion regulation strategies and identify common and differential brain areas involved in positive emotion upregulation. We acquired functional magnetic resonance imaging data from healthy college student volunteers while they upregulated positive emotions through instructed strategies or by viewing positive pictures. The instructed strategies included Attentional Deployment, Cognitive Change, and Response Modulation. These strategies increased subjective positive emotions and activation of the prefrontal cortex (PFC) and anterior cingulate cortex (ACC). Region of interest analysis revealed greater activation of the ventral striatum during positive emotion regulation. There are different networks involved in Cognitive Change and Response Modulation. Our findings indicate that multiple strategies for positive emotion upregulation involve common (e.g., PFC, ACC, and ventral striatum) and unique networks.


Subject(s)
Brain Mapping , Emotional Regulation , Brain/diagnostic imaging , Brain Mapping/methods , Emotions/physiology , Humans , Magnetic Resonance Imaging/methods
6.
Ther Drug Monit ; 44(3): 396-403, 2022 06 01.
Article in English | MEDLINE | ID: mdl-34407000

ABSTRACT

BACKGROUND: The optimal sampling points and thresholds for initial serum vancomycin (VCM) concentrations have not been determined in hemodialysis (HD) patients. To clarify this, multiple blood tests were performed, and the correlations between VCM concentrations at several sampling points and the area under the concentration-time curve for 24 hours (AUC24h) were analyzed. METHODS: A single-center, prospective observational study was conducted. Patients with end-stage renal failure who received VCM treatment while undergoing chronic maintenance HD were enrolled in this study. HD was performed using a high-flux membrane as the dialyzer. After VCM administration, 7 points were sampled between the first and second HD. The AUC24h after the end of the first HD (AUC0-24) and that before the end of the second HD (AUC24-48) were calculated using the linear trapezoidal method. Correlation analysis and simple regression analysis between AUC24h and serum concentrations were performed at each sampling point. RESULTS: Nine patients were evaluated. Strong correlations were found between AUC24-48 and serum concentrations at 24 hours after the initiation of VCM treatment following the first HD (C24h, R = 0.983 and P < 0.001), between AUC0-24 and C24h (R = 0.967 and P < 0.001), and between AUC24-48 and serum concentration just before the second HD (Cpre(HD2), R = 0.965 and P < 0.001). Regression equations with high coefficients of determination (R2 > 0.9) were obtained, and a C24h of ≥18.0 mg/L and a Cpre(HD2) of ≥16.5 mg/L were required to achieve an AUC24-48 value of ≥400 mg·h/L. In addition, a C24h of ≤23.3 mg/L was estimated to satisfy the AUC0-24 range of ≤600 mg·h/L. CONCLUSIONS: C24h and Cpre(HD2) are optimal sampling points for predicting VCM-AUC24h in HD patients.


Subject(s)
Anti-Bacterial Agents , Vancomycin , Aged , Anti-Bacterial Agents/therapeutic use , Humans , Japan , Prospective Studies , Renal Dialysis
7.
Drug Metab Dispos ; 49(4): 289-297, 2021 04.
Article in English | MEDLINE | ID: mdl-33446524

ABSTRACT

Growing evidence suggests that certain glucuronides function as potent inhibitors of CYP2C8. We previously reported the possibility of drug-drug interactions between candesartan cilexetil and paclitaxel. In this study, we evaluated the effects of candesartan N2-glucuronide and candesartan acyl-ß-D-glucuronide on pathways associated with the elimination of paclitaxel, including those involving organic anion-transporting polypeptide (OATP) 1B1, OATP1B3, CYP2C8, and CYP3A4. UDP-glucuronosyltransferase (UGT) 1A10 and UGT2B7 were found to increase candesartan N2-glucuronide and candesartan acyl-ß-D-glucuronide formation in a candesartan concentration-dependent manner. Additionally, the uptake of candesartan N2-glucuronide and candesartan acyl-ß-D-glucuronide by cells stably expressing OATPs is a saturable process with K m of 5.11 and 12.1 µM for OATP1B1 and 28.8 and 15.7 µM for OATP1B3, respectively; both glucuronides exhibit moderate inhibition of OATP1B1/1B3. Moreover, the hydroxylation of paclitaxel was evaluated using recombinant CYP3A4 and CYP3A5. Results show that candesartan, candesartan N2-glucuronide, and candesartan acyl-ß-D-glucuronide inhibit the CYP2C8-mediated metabolism of paclitaxel, with candesartan acyl-ß-D-glucuronide exhibiting the strongest inhibition (IC50 is 18.9 µM for candesartan acyl-ß-D-glucuronide, 150 µM for candesartan, and 166 µM for candesartan N2-glucuronide). However, time-dependent inhibition of CYP2C8 by candesartan acyl-ß-D-glucuronide was not observed. Conversely, the IC50 values of all the compounds are comparable for CYP3A4. Taken together, these data suggest that candesartan acyl-ß-D-glucuronide is actively transported by OATPs into hepatocytes, and drug-drug interactions may occur with coadministration of candesartan and CYP2C8 substrates, including paclitaxel, as a result of the inhibition of CYP2C8 function. SIGNIFICANCE STATEMENT: This study demonstrates that the acyl glucuronidation of candesartan to form candesartan acyl-ß-D-glucuronide enhances CYP2C8 inhibition while exerting minimal effects on CYP3A4, organic anion-transporting polypeptide (OATP) 1B1, and OATP1B3. Thus, candesartan acyl-ß-D-glucuronide might represent a potential mediator of drug-drug interactions between candesartan and CYP2C8 substrates, such as paclitaxel, in clinical settings. This work adds to the growing knowledge regarding the inhibitory effects of glucuronides on CYP2C8.


Subject(s)
Benzimidazoles/metabolism , Biphenyl Compounds/metabolism , Cytochrome P-450 CYP2C8/metabolism , Glucuronides/metabolism , Microsomes, Liver/metabolism , Tetrazoles/metabolism , Benzimidazoles/pharmacology , Biphenyl Compounds/pharmacology , Glucuronides/pharmacology , Glucuronosyltransferase/metabolism , HEK293 Cells , Humans , Liver/drug effects , Liver/metabolism , Liver-Specific Organic Anion Transporter 1/metabolism , Microsomes, Liver/drug effects , Solute Carrier Organic Anion Transporter Family Member 1B3/metabolism , Tetrazoles/pharmacology
8.
Biol Pharm Bull ; 43(8): 1253-1258, 2020.
Article in English | MEDLINE | ID: mdl-32741946

ABSTRACT

Long-term combination treatment with lenalidomide and low-dose dexamethasone is important to achieve a curative effect in patients with multiple myeloma (MM). In this study, the plasma concentration of lenalidomide was measured at 3 h after oral administration, when the drug is in the elimination phase and can be easily measured in outpatients, to identify factors that may lead to the discontinuation of this combination therapy. Patients were assigned to continuation or discontinuation of therapy groups, and the baseline characteristics of patients, lenalidomide concentration, and concentration/dose (C/D) ratios reflecting oral clearance were compared between the two groups. The efficacy and severity of adverse events were also compared. The results showed that patients who discontinued or modified treatment had low plasma concentrations of lenalidomide and C/D ratios, indicating high oral clearance of lenalidomide. The estimated creatinine clearance rate was negatively correlated with the C/D ratio. The plasma concentrations of lenalidomide were independent from kidney function and differed significantly among patients. Taken together, the results indicate that low plasma concentrations of lenalidomide and low C/D ratios may lead to discontinuation of combination therapy in patients with MM. This suggests that early measurement of lenalidomide plasma continuation would help to prevent discontinuation of therapy or a delay in modifying the dose of lenalidomide.


Subject(s)
Dexamethasone/administration & dosage , Lenalidomide/administration & dosage , Multiple Myeloma/drug therapy , Adult , Aged , Aged, 80 and over , Drug Therapy, Combination , Female , Humans , Lenalidomide/adverse effects , Lenalidomide/blood , Male , Metabolic Clearance Rate , Middle Aged
9.
Anticancer Res ; 40(2): 813-823, 2020 Feb.
Article in English | MEDLINE | ID: mdl-32014924

ABSTRACT

BACKGROUND/AIM: Olaparib was previously shown to synergistically enhance the cytotoxicity of DNA synthesis inhibitors in oesophageal carcinoma (OC) cell lines. However, the mechanisms of this synergy are not fully understood. As P53 binding protein 1 (53BP1) expression was previously shown to potentiate the anticancer effect of olaparib, we investigated the involvement of 53BP1 in the synergetic cytotoxic effects of olaparib and anticancer drugs in KYSE70 cells. MATERIALS AND METHODS: Experiments included small interfering RNA transfection, growth inhibition assays, western blots, immunofluorescence, and flow cytometry. RESULTS: The toxicity of DNA synthesis-inhibiting agents plus olaparib was decreased when 53BP1 was depleted. Olaparib cotreatment significantly increased phosphorylated H2A histone family member X (γH2AX) foci as well as 53BP1/γH2AX co-localisation in anticancer drug-treated cells. Silencing of 53BP1 suppressed anticancer drug-induced apoptosis with or without olaparib. CONCLUSION: Olaparib potentiates the cytotoxicity of anticancer drugs through 53BP1 in OC cells.


Subject(s)
Esophageal Squamous Cell Carcinoma/drug therapy , Phthalazines/therapeutic use , Piperazines/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use , Tumor Suppressor p53-Binding Protein 1/drug effects , Cell Line, Tumor , Cell Proliferation , Humans , Phthalazines/pharmacology , Piperazines/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors/pharmacology , Transfection
10.
J Clin Pharm Ther ; 45(2): 373-375, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31671217

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Oxaliplatin is a platinum drug used for treating digestive cancers that can lead to drug-induced thrombocytopenia (DITP). We report a case of oxaliplatin-induced anaphylaxis and DITP, complicated by idiosyncratic drug-induced liver injury (IDILI). CASE SUMMARY: A 46-year-old woman with rectal cancer developed anaphylaxis shortly after oxaliplatin administration (post-operative CapeOX), presenting with low platelet count (0.2 × 104 /µL) and elevated aspartate aminotransferase (1091 IU/L) and alanine aminotransferase (1010 IU/L) by day 10. Following 50 mg/d prednisolone administration from day 9, she left the hospital on day 36 after recovering. WHAT IS NEW AND CONCLUSION: This is the first case report of oxaliplatin-induced IDILI and its effective treatment with steroids.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Oxaliplatin/adverse effects , Thrombocytopenia/chemically induced , Anaphylaxis/chemically induced , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Chemical and Drug Induced Liver Injury/drug therapy , Female , Glucocorticoids/administration & dosage , Humans , Middle Aged , Oxaliplatin/administration & dosage , Prednisolone/administration & dosage , Rectal Neoplasms/drug therapy
11.
Sci Rep ; 9(1): 15464, 2019 10 29.
Article in English | MEDLINE | ID: mdl-31664047

ABSTRACT

Pharmacokinetics of SN-38 in patients with end-stage kidney disease (ESKD) is partially varied because of fluctuations in transporters expression and/or function by high protein bound-uremic toxins concentration. The fluctuations may induce variations in anticancer drugs sensitivity to cancer cells. We aimed to clarify the variations in sensitivity of SN-38 to cancer patients with ESKD and investigate this mechanism, by human colon cancer cells exposed to uremic serum residue. LS180 cells were exposed to normal or uremic serum residue (LS/NSR or LS/USR cells) for a month. IC50 values of SN-38 in LS/NSR or LS/USR cells were calculated from viability of each cells treated SN-38. mRNA expression and intracellular SN-38 accumulation was evaluated by RT-PCR and HPLC-fluorescence methods, respectively. The IC50 value in LS/USR cells was higher than that in LS/NSR cells. Organic anion transporter polypeptide (OATP) 2B1 mRNA expression was lower in LS/USR cells than in LS/NSR cells, and SN-38 accumulation in LS/USR cells was lower than that in LS/NSR cells. Only co-treatment baicalin, which is OATP2B1 inhibitor, almost negated the difference in SN-38 accumulation between LS/NSR and LS/USR. Anticancer effects of substrates of OATP2B1, such as SN-38, were reduced in ESKD patients at the same plasma substrate concentration.


Subject(s)
Irinotecan/pharmacology , Organic Anion Transporters/antagonists & inhibitors , Topoisomerase I Inhibitors/pharmacology , Uremia/blood , Cell Line, Tumor , HEK293 Cells , Humans , Irinotecan/pharmacokinetics , Kidney Failure, Chronic/metabolism , Topoisomerase I Inhibitors/pharmacokinetics
12.
Anticancer Res ; 39(4): 1813-1820, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30952721

ABSTRACT

BACKGROUND/AIM: Chemotherapy is an important first-line treatment for oesophageal squamous cell carcinoma (ESCC). However, there are few secondary options. Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, enhances the cytotoxicity of various anticancer drugs and has been used to treat advanced ovarian and breast cancers. This study examined the effect of olaparib on the cytotoxicity of anticancer drugs in ESCC cell lines. MATERIALS AND METHODS: ESCC KYSE70 and KYSE140 cells were grown in Dulbecco's modified Eagle's medium and treated with 5-fluorouracil (5-FU), cisplatin, docetaxel, doxorubicin, SN-38, or temozolomide without or with olaparib. RESULTS: Olaparib enhanced the cytotoxicity of all tested anticancer drugs and increased the effects of cisplatin, doxorubicin, SN-38, and temozolomide synergistically. These anticancer drugs caused the accumulation of phospho-histone H2AX Ser139 (γH2AX), a biomarker of DNA damage, and olaparib increased this accumulation. CONCLUSION: PARP inhibitors may potentiate the anticancer activity of DNA-damaging agents in ESCC patients synergistically.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Cisplatin/pharmacology , DNA Damage , Doxorubicin/pharmacology , Esophageal Squamous Cell Carcinoma/drug therapy , Irinotecan/pharmacology , Phthalazines/pharmacology , Piperazines/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors/pharmacology , Temozolomide/pharmacology , Cell Line, Tumor , Dose-Response Relationship, Drug , Drug Synergism , Esophageal Squamous Cell Carcinoma/genetics , Esophageal Squamous Cell Carcinoma/metabolism , Esophageal Squamous Cell Carcinoma/pathology , Histones/metabolism , Humans , Phosphorylation
13.
Ther Apher Dial ; 23(2): 126-132, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30318712

ABSTRACT

Patients with end-stage renal disease have increased plasma concentrations of statins, which is a risk factor for rhabdomyolysis, as well as elevated levels of uremic toxins (UTs). We investigated the effects of uremic serum residue and UTs on organic anion-transporting peptide (OATP1B1)- and OATP1B3-mediated pravastatin uptake. We evaluated the effects of normal serum residue with four UTs (hippuric acid, 3-carboxy-4-methyl-5-propyl-2-furan propionate, indole-3-acetic acid, and 3-indoxyl sulfate) and uremic serum residue on pravastatin uptake by OATP1B1- or OATP1B3-expressing HEK293 cells. Furthermore, we assessed the contribution of each transporter using cryopreserved human hepatocytes. Uremic serum residue and UTs significantly inhibited OATP1B1-mediated pravastatin uptake. Uremic serum residue accelerated OATP1B3-mediated pravastatin uptake, while UTs had no effect. There was no difference in pravastatin uptake between uremic- and normal serum residue-treated hepatocytes. The results suggest that the effects of uremic serum on pravastatin hepatic uptake may be considered negligible in end-stage renal disease patients.


Subject(s)
Liver-Specific Organic Anion Transporter 1/metabolism , Pravastatin/pharmacokinetics , Solute Carrier Organic Anion Transporter Family Member 1B3/metabolism , Toxins, Biological/blood , Biological Transport , Cells, Cultured , HEK293 Cells , Hepatocytes/metabolism , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/physiopathology , Uremia/metabolism
14.
Oncol Lett ; 16(5): 6202-6208, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30333885

ABSTRACT

Resistance to 5-fluorouracil (5-FU) is a serious problem in cancer therapy and overcoming it is required in order to improve the efficacy of cancer chemotherapy. Histone deacetylase (HDAC) inhibitors are used in cancer treatments and, recently, it has been reported that HDAC inhibitors can overcome resistance to various anti-cancer drugs in vitro. In the present study, a 5-FU-resistant breast cancer cell line was established, and the effects of HDAC inhibitors in these cells were examined. The 5-FU-resistant cell line MDA-MB-468 (MDA468/FU) was established by continuous exposure of the parental cells to 5-FU. This subline was characterized by high resistance to 5-FU, higher mRNA expression levels of thymidylate synthetase and dihydropyrimidine dehydrogenase (DPD), and lower mRNA expression levels of uridine monophosphate synthetase (UMPS) than the parental cells. Gimeracil, a DPD inhibitor, did not affect the sensitivity of MDA468/FU cells to 5-FU. Oteracil, a UMPS inhibitor, decreased the cytotoxicity of 5-FU in MDA468 cells, but not in MDA468/FU cells. The HDAC inhibitors, valproic acid and suberanilohydroxamic acid sensitized the two cell lines to 5-FU in a concentration-dependent manner. In conclusion, the results of the present study revealed that HDAC inhibitors increase the sensitivity to 5-FU in 5-FU-sensitive and -resistant cells.

15.
Int J Clin Pharmacol Ther ; 56(7): 328-336, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29792394

ABSTRACT

OBJECTIVE: Angiotensin receptor blockers (ARBs) are often used in patients on paclitaxel (PTX) and carboplatin combination (TC) therapy to treat hypertension caused by the co-administration of bevacizumab. The aim of this retrospective study was to analyze the association between co-administration of ARBs and the development of severe neutropenia in patients on TC therapy. MATERIALS AND METHODS: In this study, 211 concomitant medications were prescribed to 173 patients on TC therapy. 24 of those patients received ARBs. The incidences of neutropenia among those on various ARBs were compared. RESULTS: Patients on candesartan cilexetil had the highest incidence of neutropenia compared to those on other concomitant medications, including other ARBs. Of 173 patients, 6 received candesartan cilexetil during the first cycle of TC therapy, and all 6 of them developed severe neutropenia. We noted that prior to TC therapy, there were no significant differences in age, serum albumin levels, neutrophil counts, liver injury marker, and renal function between the patients on candesartan cilexetil and those on other ARBs. CONCLUSION: Our data suggest that a drug-drug interaction between candesartan cilexetil and TC therapy is probable. Unlike with other ARBs, the possible increased risk for development of severe neutropenia should be taken into account when prescribing candesartan cilexetil in combination with TC therapy.
.


Subject(s)
Angiotensin II Type 1 Receptor Blockers/adverse effects , Antihypertensive Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Benzimidazoles/adverse effects , Biphenyl Compounds/adverse effects , Blood Pressure/drug effects , Carboplatin/adverse effects , Hypertension/drug therapy , Neutropenia/chemically induced , Paclitaxel/adverse effects , Tetrazoles/adverse effects , Aged , Aged, 80 and over , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Antihypertensive Agents/administration & dosage , Benzimidazoles/administration & dosage , Biphenyl Compounds/administration & dosage , Drug Interactions , Female , Humans , Hypertension/chemically induced , Hypertension/epidemiology , Hypertension/physiopathology , Incidence , Japan/epidemiology , Male , Middle Aged , Neutropenia/blood , Neutropenia/diagnosis , Neutropenia/epidemiology , Retrospective Studies , Risk Factors , Severity of Illness Index , Tetrazoles/administration & dosage , Time Factors , Treatment Outcome
16.
J Pharm Pharmacol ; 70(8): 1040-1047, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29761837

ABSTRACT

OBJECTIVES: Tumour hypoxia is a major obstacle in cancer therapy that leads to poor prognosis. Therefore, the development of cancer treatments that are effective in hypoxia is necessary. Nitrogen-containing bisphosphonates (N-BPs), which are used to treat bone disease, are cytotoxic to several cancer cells in normoxia. Therefore, we investigated the cytotoxicity of N-BPs in cancer cells in hypoxia. METHODS: We studied the cytotoxicities of N-BPs, statins and anticancer drugs in human cancer cells under hypoxic conditions (1% O2 ). The expression levels of enzymes in the mevalonate pathway in hypoxia were measured by real-time reverse transcription polymerase chain reaction and Western blotting. KEY FINDINGS: In hypoxia, cell growth inhibition by 5-fluorouracil and cisplatin was not changed as compared to that in normoxia; however, cell growth inhibition by N-BPs and via zoledronate-induced apoptosis was higher in hypoxia than that in normoxia. Furthermore, geranylgeraniol completely inhibited the growth inhibitory effects of zoledronate. Additionally, the mRNA and protein levels of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase significantly decreased in hypoxia. Moreover, simvastatin potentiated the growth inhibitory effect of zoledronate. CONCLUSIONS: The cytotoxicity of N-BPs, but not 5-fluorouracil and cisplatin, is potentiated in hypoxia, through the loss of HMG-CoA reductase function. N-BPs may be effective against cancer in normoxia and hypoxia.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cell Hypoxia/drug effects , Diphosphonates/pharmacology , Imidazoles/pharmacology , Oxygen/metabolism , A549 Cells , Cell Survival/drug effects , Dose-Response Relationship, Drug , Drug Synergism , Gene Expression/drug effects , HeLa Cells , Humans , Hydroxymethylglutaryl CoA Reductases/metabolism , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Simvastatin/pharmacology , Zoledronic Acid
17.
Cancer Chemother Pharmacol ; 81(6): 1121-1128, 2018 06.
Article in English | MEDLINE | ID: mdl-29693202

ABSTRACT

PURPOSE: Pharmacokinetics and pharmacodynamics of irinotecan have been reported to be altered in cancer patients with end-stage kidney disease (ESKD). Carboxylesterase (CES) has an important role in metabolism of irinotecan to its active metabolite, SN-38, in human liver. The purpose of the present study was to investigate whether CES activity was altered in ESKD patients. METHODS: The present study investigated the effects of uremic serum, uremic toxins, and fatty acids on the hydrolysis of irinotecan and a typical CES substrate, p-nitrophenyl acetate (PNPA), in human liver microsomes. Normal and uremic serum samples were deproteinized by treatment with methanol were used in the present study. RESULTS: The present study showed that both normal and uremic serum significantly inhibited CES-mediated metabolism of both irinotecan and PNPA. The inhibition by uremic serum was weaker than that by normal serum, suggesting that CES activity may be higher in ESKD patients. Although four uremic toxins did not affect PNPA metabolism, arachidonic acid inhibited it. There was no difference in inhibitory effect of PNPA metabolism between both mixtures of seven fatty acids used at concentrations equivalent to those present in 10% normal or uremic serum. Interestingly, those mixtures had a more pronounced effect than either 10% normal or uremic serum. CONCLUSIONS: The present study showed that the inhibition of CES activity by uremic serum was weaker than that by normal serum, suggesting that an increase in maximum plasma concentration of SN-38 in cancer patients with ESKD can be attributed to an accelerated CES-mediated irinotecan hydrolysis.


Subject(s)
Carboxylesterase/metabolism , Irinotecan/pharmacokinetics , Kidney Failure, Chronic/metabolism , Microsomes, Liver/metabolism , Topoisomerase I Inhibitors/pharmacokinetics , Case-Control Studies , Fatty Acids/metabolism , Humans , Kidney Failure, Chronic/enzymology , Microsomes, Liver/enzymology , Nitrophenols/metabolism , Uremia/metabolism
18.
Toxins (Basel) ; 10(2)2018 01 25.
Article in English | MEDLINE | ID: mdl-29370118

ABSTRACT

Patients with end-stage kidney disease (ESKD) are at higher risk for rhabdomyolysis induced by statin than patients with normal kidney function. Previously, we showed that this increase in the severity of statin-induced rhabdomyolysis was partly due to uremic toxins. However, changes in the quantity of various trace elements in ESKD patients likely contribute as well. The purpose of this study is to determine the effect of trace elements on statin-induced toxicity in rhabdomyosarcoma cells exposed to uremic serum (US cells) for a long time. Cell viability, apoptosis, mRNA expression, and intracellular trace elements were assessed by viability assays, flow cytometry, real-time RT-PCR, and ICP-MS, respectively. US cells exhibited greater simvastatin-induced cytotoxicity than cells long-time exposed with normal serum (NS cells) (non-overlapping 95% confidence intervals). Intracellular levels of Mg, Mn, Cu, and Zn were significantly less in US cells compared to that in NS cells (p < 0.05 or 0.01). Pre-treatment with TPEN increased simvastatin-induced cytotoxicity and eliminated the distinction between both cells of simvastatin-induced cytotoxicity. These results suggest that Zn deficiencies may be involved in the increased risk for muscle complaints in ESKD patients. In conclusion, the increased severity of statin-induced rhabdomyolysis in ESKD patients may be partly due to trace elements deficiencies.


Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/toxicity , Metals/metabolism , Rhabdomyosarcoma/metabolism , Serum , Uremia , Cell Line, Tumor , Cell Survival/drug effects , Cisplatin/toxicity , Humans , Kidney Failure, Chronic/metabolism , Losartan/toxicity , Rhabdomyolysis/metabolism , Simvastatin/toxicity , Superoxide Dismutase/genetics
19.
Xenobiotica ; 48(10): 1059-1071, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29034773

ABSTRACT

1. Organic anion-transporting polypeptide 1B1 (OATP1B1) plays an important role in the hepatic uptake of a broad range of substrate drugs. In vitro experiments show that molecular-targeted agents do not always have similar effects on OATP1B1 activity. 2. The purpose of this study was to clarify whether the effects of molecular-targeted agents on OATP1B1 are substrate-dependent. We used OATP1B1-transfected cells to compare the effects of molecular-targeted agents on OATP1B1-mediated uptake of fluorescein (FL), 2',7'-dichlorofluorescein (DCF), atorvastatin, SN-38 and valsartan. 3. Cabozantinib, cediranib, neratinib, pazopanib, regorafenib, sorafenib and tivantinib did not affect or only slightly affected OATP1B1-mediated substrate uptake. Nilotinib and lenvatinib moderately and strongly inhibited OATP1B1-mediated substrate uptake, respectively. In contrast, afatinib stimulated OATP1B1-mediated uptake of FL and SN-38, ceritinib stimulated that of valsartan, and nintedanib stimulated that of FL and valsartan. In addition, the effects of afatinib, ceritinib and nintedanib on OATP1B1 activity differed markedly depending on the type of substrate. Afatinib, ceritinib and nintedanib had a substrate-dependent effect on OATP1B1 activity. 4. We conclude that the evaluation of OATP1B1 activity using only a single probe substrate for some molecular-targeted agents may lead to a faulty understanding of their mechanisms of drug interactions.


Subject(s)
Antineoplastic Agents/pharmacology , Liver-Specific Organic Anion Transporter 1/metabolism , Molecular Targeted Therapy , Antineoplastic Agents/chemistry , Drug Interactions , Fluorescein/metabolism , Fluoresceins/metabolism , HEK293 Cells , Humans , Inhibitory Concentration 50 , Kinetics , Substrate Specificity/drug effects
20.
Biol Pharm Bull ; 40(9): 1561-1565, 2017.
Article in English | MEDLINE | ID: mdl-28867739

ABSTRACT

Human intestinal absorption and drug metabolism vary to a large extent among individuals. For example, CYP3A4 activity has large individual variation that cannot be attributed to only genetic differences. Various flavonoids in vegetables, such as kaempferol and quercetin, possess inhibitory effects, and some vegetable and fruit juices have also been found to inhibit CYP3A4 activity. Therefore, differences in daily intake of flavonoid-containing vegetables may induce individual variation in intestinal bioavailability. To identify a vegetable that strongly inhibits CYP3A4, we investigated the effects of juices, prepared from individual vegetables, on CYP3A4 activity using recombinant CYP3A4 and LS180 cells in this study. Nine vegetable juices (cabbage, Japanese radish, onion, tomato, eggplant, carrot, Chinese cabbage, green pepper, and lettuce), were prepared and recombinant CYP3A4 and LS180 cells were used for evaluation of CYP3A4 activity. Metabolism to 6ß-hydroxytestosterone by recombinant CYP3A4 was strongly inhibited by cabbage, onion, and green pepper juices, and cabbage and green pepper juices significantly inhibited CYP3A4 activity in a preincubation time-dependent manner. In addition, CYP3A4 activity in LS180 cells was significantly inhibited by cabbage and onion juices. In conclusion, this study showed that juices prepared from some individual vegetables could significantly inhibit CYP3A4 activity. Therefore, variation in the daily intake of vegetables such as cabbage and onion may be one of the factors responsible for individual differences in intestinal bioavailability.


Subject(s)
Beverages , Cytochrome P-450 CYP3A Inhibitors/pharmacology , Cytochrome P-450 CYP3A/metabolism , Vegetables/chemistry , Biological Availability , Cell Line , Humans , Hydroxytestosterones/metabolism , Pharmaceutical Preparations/metabolism , Plant Extracts/pharmacology , Recombinant Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...